Page 28 - Brainstorm Cell News Today

U.S. health regulators have approved a first-of-a-kind drug for a rare form of Lou Gehrig’s disease. The Food and Drug Administration approved Biogens infused drug for patients with a rare

WASHINGTON (AP) — Food and Drug Administration regulators on Tuesday approved a first-of-a-kind drug for a rare form of Lou Gehrig’s disease, though they are requiring further research to confirm

U.S. health regulators have approved a first-of-a-kind drug for a rare form of Lou Gehrig’s disease. The Food and Drug Administration approved Biogen's infused drug for patients with a rare genetic mutation that affects less than 500 people in the U.S. The drug is the first intended to treat an inherited form of ALS, or amyotrophic lateral sclerosis, which destroys nerve cells needed for basic functions. Tuesday's approval came despite a company study that failed to meet its goal of ...

Approval came via FDA’s accelerated pathway, which allows drugs to launch based on promising early results, before they’re confirmed to benefit patients

The FDA on Tuesday approved tofersen, a drug from Biogen that is the first drug for an inherited form of ALS.

The drug, Qalsody, is the first of its kind for a rare form of ALS.

Drug For Rare Form Of Lou Gehrig’s Disease (ALS) Approved By FDA

Approval came via FDA’s accelerated pathway, which allows drugs to launch based on promising early results, before they’re confirmed to benefit patients

Approval came via FDA’s accelerated pathway, which allows drugs to launch based on promising early results, before they’re confirmed to benefit patients

Food and Drug Administration regulators on Tuesday approved the drug tofersen, a first-of-its-kind treatment for a rare, inherited form of ALS.